Abnormal weight gain with fatigue and stress in early survivorship after childhood brain tumor diagnosis.
Abnormal weight gain with fatigue and stress in early survivorship after childhood brain tumor diagnosis.
复制标题
儿童脑肿瘤诊断后早期生存中体重异常增加并伴有疲劳和压力。
DOI:
10.1111/jspn.12288
复制
发表时间:
2020
期刊:
影响因子:
--
通讯作者:
Rice,Marti
中科院分区:
文献类型:
--
作者:
Johnson,AnnH;RodgersPhillips,Shameka;Rice,Marti
BackgroundDiagnosis and treatment for individuals with brain tumors during childhood involves sequelae, including abnormal weight gain. This symptom is commonly clustered with fatigue and increased risk for cardiovascular disease. Children's Oncology Group recommendations include annual surveillance of body mass index (BMI) and cardiometabolic comorbidities; however, there has been little emphasis on individualized screening early in survivorship.PurposeThe primary purpose of this paper is to describe the findings of abnormal weight gain and its correlates in a sample of young childhood brain tumor survivors during early survivorship.Design and MethodsThis cross‐sectional multi‐site study included brain tumor survivors of ages 8–12 years who were less than 6 years posttreatment. Convenience sampling from two pediatric cancer centers in the southern United States was utilized. Data collected included BMI, parent report of sleep, and child report of fatigue and stress.ResultsThe sample (N= 21) consisted of children who had received chemotherapy, radiation treatment, and surgery for childhood brain tumor. BMI in overweight and obese categories exceeded normative samples with 38% at or above the 85th percentile. There were clinically significant relationships with fatigue, stress about weight, tumor location, cranial radiation, chemotherapy, and recurrencePractice ImplicationsScreening for abnormal weight gain and related factors, such as fatigue should begin early in survivorship after childhood brain tumor treatment completion with the aim of health promotion and disease prevention. Adiposity measurement techniques should be utilized in future clinical and research settings to improve assessment of cardiometabolic risk.